Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03150862
Recruitment Status : Completed
First Posted : May 12, 2017
Last Update Posted : April 19, 2021
Sponsor:
Information provided by (Responsible Party):
BeiGene ( BeiGene USA, Inc. )

Brief Summary:
The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Drug: Pamiparib Drug: TMZ Radiation: Radiation Phase 1 Phase 2

Detailed Description:

An open-label, multiple-dose, dose-escalation study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of Pamiparib in combination with radiation therapy (RT) and/or TMZ.

In dose escalation/Phase 1b, Pamiparib will be combined with RT (Arm A) or RT and TMZ (Arm B) in participants with newly diagnosed unmethylated glioblastoma (GBM) and in Arm C of the study Pamiparib will be combined with TMZ in participants with methylated or unmethylated recurrent/refractory GBM.

The dose expansion/Phase 2 phase will enroll up to 4 cohorts: participants with newly diagnosed unmethylated GBM in Arms A and B, and 2 cohorts of participants with recurrent/refractory GBM grouped by O-6-methylguanine-DNA methyltransferase (MGMT) status - unmethylated or methylated - in Arm C.

Participants in Arms A and B are treated until completion of RT and participants in Arm C may continue treatment in the absence of safety concerns and disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: No Masking
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Actual Study Start Date : August 1, 2017
Actual Primary Completion Date : March 17, 2021
Actual Study Completion Date : March 17, 2021


Arm Intervention/treatment
Experimental: Arm A (Dose Escalation)
Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
Drug: Pamiparib
Administered as specified in the treatment arm
Other Name: BGB-290

Radiation: Radiation
Up to 60 Gy (total) over 6 - 7 weeks

Experimental: Arm B (Dose Escalation)
Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
Drug: Pamiparib
Administered as specified in the treatment arm
Other Name: BGB-290

Drug: TMZ
Administered as specified in the treatment arm

Radiation: Radiation
Up to 60 Gy (total) over 6 - 7 weeks

Experimental: Arm A (Dose Expansion)
Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
Drug: Pamiparib
Administered as specified in the treatment arm
Other Name: BGB-290

Radiation: Radiation
Up to 60 Gy (total) over 6 - 7 weeks

Experimental: Arm B (Dose Expansion)
Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
Drug: Pamiparib
Administered as specified in the treatment arm
Other Name: BGB-290

Drug: TMZ
Administered as specified in the treatment arm

Radiation: Radiation
Up to 60 Gy (total) over 6 - 7 weeks

Experimental: Arm C (Dose Escalation)
Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
Drug: Pamiparib
Administered as specified in the treatment arm
Other Name: BGB-290

Drug: TMZ
Administered as specified in the treatment arm

Experimental: Arm C (Dose Expansion-Cohorts C1 and C2)
Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
Drug: Pamiparib
Administered as specified in the treatment arm
Other Name: BGB-290

Drug: TMZ
Administered as specified in the treatment arm




Primary Outcome Measures :
  1. Phase 1b: Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE [ Time Frame: Time Frame: From first dose Pamiparib + RT +/- TMZ to up to 10 weeks post-dose (Arms A and B) . From first dose Pamiparib +TMZ to 28 days post-dose (Arm Cv) ]
  2. Phase 1b: Incidence, nature and severity of adverse events as assessed by CTCAE [ Time Frame: From first dose Pamiparib + RT +/- TMZ to 30 days post final dose of pamiparib +/- RT or TMZ ]
  3. Phase 1b: Number of treatment cycles (Arm C only), dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment [ Time Frame: From first dose Pamiparib + RT +/- TMZ to 30 days post final dose of pamiparib +/- RT or TMZ ]
  4. Phase 2 Arm A [Pamiparib + RT] and Arm B [Pamiparib + RT + TMZ]: Modified disease control rate (mDCR) using modified Response Assessment in Neuro-oncology (mRANO) [ Time Frame: From first dose Pamiparib to first documentation of progression while participant is alive, assessed up to 5 years. ]
  5. Phase 2 Arm C [Pamiparib + TMZ]: Objective response rate (ORR) using mRANO [ Time Frame: Time Frame: From first dose of Pamiparib to first documentation of progression while participant is alive assessed up to 5 years.] ]
    Objective response rate (ORR) using mRANO


Secondary Outcome Measures :
  1. Pharmacokinetic (PK) parameters of Pamiparib of steady state Ctrough [ Time Frame: From first dose Pamiparib to 30 days post-final dose of pamiparib +/- RT or TMZ. ]
  2. Disease control rate [ Time Frame: From first dose Pamiparib to first documentation of disease progression while participant is alive assessed up to 5 years. ]
  3. Objective response rate (ORR) [ Time Frame: From first dose Pamiparib to first documentation of disease progression while participant is alive assessed up to 5 years. ]
  4. Clinical benefit rate (CBR) [ Time Frame: From first dose Pamiparib to first documentation of disease progression while participant is alive assessed up to 5 years. ]
  5. Duration of response (DOR) [ Time Frame: From first documentation of CR or PR to first documentation of progression or death, assessed up to 5 years ]
  6. Progression free survival (PFS). [ Time Frame: From first dose Pamiparib to first documentation of progression or death, assessed up to 5 years ]
  7. Overall survival (OS) [ Time Frame: From first dose Pamiparib until date of death, assessed up to 5 years. ]
  8. Incidence, nature and severity of adverse events as assessed by CTCAE [ Time Frame: From first dose Pamiparib + RT +/- TMZ to 30 days post- last dose of pamiparib or RT whichever is later ]
    Phase 2 (Arm A and Arm B)

  9. Length of treatment, dose intensity of components of each treatment , and changes in vital signs and clinical laboratory tests during and following treatment [ Time Frame: From first dose Pamiparib + RT +/- TMZ to 30 days post- last dose of pamiparib or RT whichever is later ]
    Phase 2 (Arm A and Arm B)

  10. PK parameter of Pamiparib of steady state Ctrough [ Time Frame: From first dose Pamiparib to 30 days post dose. ]
    Phase 2 (Arm A and Arm B)

  11. Incidence, nature and severity of adverse events as assessed by CTCAE [ Time Frame: From first dose Pamiparib + TMZ to 30 days post last dose Pamiparib or TMZ, whichever is later). ]
    Phase 2 (Arm C)

  12. Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment [ Time Frame: From first dose Pamiparib + TMZ to 30 days post last dose Pamiparib or TMZ (whichever is later). ]
    Phase 2 (Arm C)

  13. PK parameter of Pamiparib of steady state Ctrough [ Time Frame: From first dose Pamiparib to 30 days post dose. ]
    Phase 2 (Arm C)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria: All participants

  1. Age ≥ 18 years old.
  2. Confirmed diagnosis of glioblastoma (WHO Grade IV).
  3. Agreement to provide archival tumor tissue for exploratory biomarker analysis
  4. Ability to undergo serial MRIs.
  5. Eastern Cooperative Oncology Group (ECOG) status ≤ 1.
  6. Adequate hematologic and end-organ function
  7. Females of childbearing potential and non-sterile males must agree to use highly effective methods of birth control throughout the course of study and at least up to 6 months after last dosing.
  8. Ability to swallow whole capsules.

    Participants in Arms A and B (not Arm C) must meet inclusion criteria # 9 - 11:

  9. No previous treatment for GBM except surgery.
  10. Able to start radiation therapy ≤ 49 days after surgery but ≥ 14 days after a biopsy or ≥28 days after an open biopsy or craniotomy with adequate wound healing.
  11. Documented unmethylated MGMT promoter status.

    Participants in Arm C Escalation (Phase 1b) must meet inclusion criteria # 12 - 15:

  12. Documentation of MGMT promoter status
  13. No prior systemic chemotherapy other than TMZ for GBM.
  14. Histologically confirmed secondary glioblastoma
  15. Disease that is evaluable or measurable as defined by RANO criteria

    Participants in Arm C Expansion (Phase 2), must meet criteria # 16 - 18:

  16. Histologically confirmed de novo (primary) glioblastoma with unequivocal first progressive disease (PD) after RT with concurrent/adjuvant TMZ chemotherapy
  17. Disease that is measurable as defined by RANO criteria
  18. Documentation of MGMT promoter status

Key Exclusion Criteria: All participants

  1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ≤21 days prior to start of study treatment.
  2. Toxicity of ≥ Grade 2 from prior therapy.
  3. Major surgery or significant other injury ≤ 4 weeks prior to start of study treatment.
  4. History of other active malignancies within 2 years with exception of (i) adequately treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii) localized adequately treated cancer with curative intent or malignancy diagnosed > 2 years ago with no evidence of disease and no treatment ≤ 2 years prior to study treatment.
  5. Active infection requiring systemic treatment.
  6. Known human immunodeficiency virus (HIV) or active viral hepatitis.
  7. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease, ventricular arrhythmia or Cerebrovascular Accident (CVA) ≤ 6 months prior to start of treatment.
  8. Active clinically significant gastrointestinal disease.
  9. Active bleeding disorder ≤ 6 months prior to start of treatment.
  10. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.
  11. Use of any medications or food known to be strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or strong inducers.
  12. Pregnant or nursing females.
  13. Significant intercurrent illness that may result in participant's death prior to death from glioblastoma.

    Arms B and C Only:

  14. Known hypersensitivity to any component of TMZ or decarbazine (DTIC).
  15. Have hereditary problems of galactose intolerance

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150862


Locations
Show Show 21 study locations
Sponsors and Collaborators
BeiGene USA, Inc.
Investigators
Layout table for investigator information
Study Director: Katie Wood, RN BeiGene
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: BeiGene USA, Inc.
ClinicalTrials.gov Identifier: NCT03150862    
Other Study ID Numbers: BGB-290-104
2017-001554-33 ( EudraCT Number )
First Posted: May 12, 2017    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BeiGene ( BeiGene USA, Inc. ):
Adult glioblastoma, adult giant cell glioblastoma, adult gliosarcoma, glioma neoplasms
recurrent adult brain tumor
neoplasms, central nervous system neoplasms, neoplasms by histologic type, neoplasms by site
astrocytoma
neuroepithelial
neuroectodermal tumors
germ cell and embryonal
antineoplastic agents
glandular and epithelial
nerve tissue, nervous system diseases
temozolomide
BGB-290
alkylating, alkylating agents
molecular mechanisms of pharmacological action
Poly(ADP-ribose) polymerase inhibitors
enzyme inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Nervous System Neoplasms
Central Nervous System Neoplasms
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases